CCL2 expression is mediated by type I IFN receptor and recruits NK and T cells to the lung during MVA infection
暂无分享,去创建一个
[1] A. Alcamí,et al. Immune modulation by virus-encoded secreted chemokine binding proteins. , 2015, Virus research.
[2] S. Eo,et al. Distinct Upstream Role of Type I IFN Signaling in Hematopoietic Stem Cell-Derived and Epithelial Resident Cells for Concerted Recruitment of Ly-6Chi Monocytes and NK Cells via CCL2-CCL3 Cascade , 2015, PLoS pathogens.
[3] S. Salek-Ardakani,et al. Natural Killer Cells and Innate Interferon Gamma Participate in the Host Defense against Respiratory Vaccinia Virus Infection , 2015, Journal of Virology.
[4] Abigail Hielscher,et al. The mechanisms of genetically modified vaccinia viruses for the treatment of cancer. , 2015, Critical reviews in oncology/hematology.
[5] S. Akira,et al. Alveolar macrophage–derived type I interferons orchestrate innate immunity to RSV through recruitment of antiviral monocytes , 2015, The Journal of experimental medicine.
[6] G. Pantaleo,et al. NFκB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses , 2015, Proceedings of the National Academy of Sciences.
[7] Modified Vaccinia virus Ankara but not vaccinia virus induces chemokine expression in cells of the monocyte/macrophage lineage , 2015, Virology Journal.
[8] G. Sutter,et al. Complement Component C5 Recruits Neutrophils in the Absence of C3 during Respiratory Infection with Modified Vaccinia Virus Ankara , 2015, The Journal of Immunology.
[9] G. Cheng,et al. Positive feedback regulation of type I interferon by the interferon‐stimulated gene STING , 2015, EMBO reports.
[10] G. Rimmelzwaan,et al. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. , 2014, The Lancet. Infectious diseases.
[11] M. Seshadri,et al. CXCL12/CXCR4 Blockade by Oncolytic Virotherapy Inhibits Ovarian Cancer Growth by Decreasing Immunosuppression and Targeting Cancer-Initiating Cells , 2014, The Journal of Immunology.
[12] T. Murayama,et al. Human cytomegalovirus replication supported by virus-induced activation of CCL2-CCR2 interactions. , 2014, Biochemical and biophysical research communications.
[13] A. Bowie,et al. Innate immune activation of NFκB and its antagonism by poxviruses. , 2014, Cytokine & growth factor reviews.
[14] G. Sutter,et al. Chemokine (C-C Motif) Receptor 1 Is Required for Efficient Recruitment of Neutrophils during Respiratory Infection with Modified Vaccinia Virus Ankara , 2014, Journal of Virology.
[15] Zhijian J. Chen,et al. Modified Vaccinia Virus Ankara Triggers Type I IFN Production in Murine Conventional Dendritic Cells via a cGAS/STING-Mediated Cytosolic DNA-Sensing Pathway , 2014, PLoS pathogens.
[16] H. Reyburn,et al. Differential Induction of Apoptosis, Interferon Signaling, and Phagocytosis in Macrophages Infected with a Panel of Attenuated and Nonattenuated Poxviruses , 2014, Journal of Virology.
[17] C. Maluquer de Motes,et al. Vaccinia virus immune evasion: mechanisms, virulence and immunogenicity. , 2013, The Journal of general virology.
[18] C. Garlanda,et al. Tumor associated macrophages and neutrophils in cancer. , 2013, Immunobiology.
[19] M. Esteban,et al. Clinical applications of attenuated MVA poxvirus strain , 2013, Expert review of vaccines.
[20] R. Schmidt,et al. Multifaceted Impact of Host C–C Chemokine CCL2 in the Immuno-Pathogenesis of HIV-1/M. tuberculosis Co-Infection , 2013, Front. Immunol..
[21] G. Sutter,et al. Modified Vaccinia virus Ankara: innate immune activation and induction of cellular signalling. , 2013, Vaccine.
[22] S. Kotenko,et al. Interferon induction and function at the mucosal surface , 2013, Immunological reviews.
[23] J. Arthur,et al. IFNβ autocrine feedback is required to sustain TLR induced production of MCP-1 in macrophages , 2013, FEBS letters.
[24] V. Rivera-Amill,et al. Astrocytic expression of HIV-1 Nef impairs spatial and recognition memory , 2013, Neurobiology of Disease.
[25] T. Decker,et al. The regulation of inflammation by interferons and their STATs , 2013, JAK-STAT.
[26] Christopher D. Conrady,et al. IFN-α-driven CCL2 Production Recruits Inflammatory Monocytes to Infection Site in Mice , 2012, Mucosal Immunology.
[27] Interleukin-1β receptor expressed by modified vaccinia virus Ankara interferes with interleukin-1β activity produced in various virus-infected antigen-presenting cells , 2013, Virology Journal.
[28] D. Zaiss,et al. CCR2 Defines a Distinct Population of NK Cells and Mediates Their Migration during Influenza Virus Infection in Mice , 2012, PloS one.
[29] D. Bartlett,et al. Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity. , 2012, Neoplasia.
[30] D. Duffy,et al. Neutrophils transport antigen from the dermis to the bone marrow, initiating a source of memory CD8+ T cells. , 2012, Immunity.
[31] Y. Iwakura,et al. Neutrophils orchestrate their own recruitment in murine arthritis through C5aR and FcγR signaling , 2012, Proceedings of the National Academy of Sciences.
[32] Xiaoliu Zhang,et al. Incorporation of the B18R gene of vaccinia virus into an oncolytic herpes simplex virus improves antitumor activity. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[33] J. Kreijtz,et al. Easy and efficient protocols for working with recombinant vaccinia virus MVA. , 2012, Methods in molecular biology.
[34] Oncolytic poxviruses , 2012, Molecular Genetics, Microbiology and Virology.
[35] A. Bowie,et al. Vaccinia Virus Protein C6 Is a Virulence Factor that Binds TBK-1 Adaptor Proteins and Inhibits Activation of IRF3 and IRF7 , 2011, PLoS pathogens.
[36] Jinghang Zhang,et al. CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis , 2011, Nature.
[37] S. Akira,et al. Pathogen Recognition by the Innate Immune System , 2011, International reviews of immunology.
[38] Vandana Saini,et al. MCP-1: chemoattractant with a role beyond immunity: a review. , 2010, Clinica chimica acta; international journal of clinical chemistry.
[39] R. Locksley,et al. Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands , 2009, Nature Immunology.
[40] Heather E. Lynch,et al. Modified vaccinia virus Ankara can activate NF-kappaB transcription factors through a double-stranded RNA-activated protein kinase (PKR)-dependent pathway during the early phase of virus replication. , 2009, Virology.
[41] T. Salazar-Mather,et al. Regulation of Inflammatory Monocyte/Macrophage Recruitment from the Bone Marrow during Murine Cytomegalovirus Infection: Role for Type I Interferons in Localized Induction of CCR2 Ligands1 , 2009, The Journal of Immunology.
[42] S. Akira,et al. Innate Immune Sensing of Modified Vaccinia Virus Ankara (MVA) Is Mediated by TLR2-TLR6, MDA-5 and the NALP3 Inflammasome , 2009, PLoS pathogens.
[43] W. Kastenmuller,et al. Modified Vaccinia Virus Ankara Triggers Chemotaxis of Monocytes and Early Respiratory Immigration of Leukocytes by Induction of CCL2 Expression , 2009, Journal of Virology.
[44] J. Löwer,et al. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox. , 2009, The Journal of infectious diseases.
[45] L. Anderson,et al. Respiratory Syncytial Virus Activates Innate Immunity through Toll-Like Receptor 2 , 2008, Journal of Virology.
[46] S. Akira,et al. Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. , 2008, The Journal of clinical investigation.
[47] S. Akira,et al. Modified Vaccinia Virus Ankara Induces Toll-Like Receptor-Independent Type I Interferon Responses , 2007, Journal of Virology.
[48] T. Gallart,et al. Distinct Gene Expression Profiling after Infection of Immature Human Monocyte-Derived Dendritic Cells by the Attenuated Poxvirus Vectors MVA and NYVAC , 2007, Journal of Virology.
[49] T. Hartung,et al. Cellular Recognition of Trimyristoylated Peptide or Enterobacterial Lipopolysaccharide via Both TLR2 and TLR4* , 2007, Journal of Biological Chemistry.
[50] S. Kramer,et al. HIV-1 Nef upregulates CCL2/MCP-1 expression in astrocytes in a myristoylation- and calmodulin-dependent manner , 2006, Journal of Cell Science.
[51] W. Seeger,et al. Alveolar Epithelial Cells Direct Monocyte Transepithelial Migration upon Influenza Virus Infection: Impact of Chemokines and Adhesion Molecules1 , 2006, The Journal of Immunology.
[52] A. Bowie,et al. Poxvirus Protein N1L Targets the I-κB Kinase Complex, Inhibits Signaling to NF-κB by the Tumor Necrosis Factor Superfamily of Receptors, and Inhibits NF-κB and IRF3 Signaling by Toll-like Receptors* , 2004, Journal of Biological Chemistry.
[53] J. Shisler,et al. The Vaccinia Virus K1L Gene Product Inhibits Host NF-κB Activation by Preventing IκBα Degradation , 2004, Journal of Virology.
[54] Charles L. Bailey,et al. Prevention of lethal respiratory vaccinia infections in mice with interferon-α and interferon-γ , 2004 .
[55] R. Bronson,et al. Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[56] J. Shisler,et al. The vaccinia virus K1L gene product inhibits host NF-kappaB activation by preventing IkappaBalpha degradation. , 2004, Journal of virology.
[57] Charles L. Bailey,et al. Prevention of lethal respiratory vaccinia infections in mice with interferon-alpha and interferon-gamma. , 2004, FEMS immunology and medical microbiology.
[58] A. Bowie,et al. Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors. , 2004, The Journal of biological chemistry.
[59] G. McFadden,et al. Poxviruses and immune evasion. , 2003, Annual review of immunology.
[60] Steffen Jung,et al. Blood monocytes consist of two principal subsets with distinct migratory properties. , 2003, Immunity.
[61] C. Staib,et al. Improved host range selection for recombinant modified vaccinia virus Ankara. , 2003, BioTechniques.
[62] A. Alcamí,et al. The Vaccinia Virus Soluble Alpha/Beta Interferon (IFN) Receptor Binds to the Cell Surface and Protects Cells from the Antiviral Effects of IFN , 2000, Journal of Virology.
[63] E. M. Rogers,et al. Nuclear factor-kappa B p65 mediates the assembly and activation of the TNF-responsive element of the murine monocyte chemoattractant-1 gene. , 1999, Journal of immunology.
[64] M. Rothe,et al. Human Toll-like Receptor 2 Confers Responsiveness to Bacterial Lipopolysaccharide , 1998, The Journal of experimental medicine.
[65] M Aguet,et al. Functional role of type I and type II interferons in antiviral defense. , 1994, Science.
[66] H. W. Chang,et al. The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[67] M. Jordan. Interstitial pneumonia and subclinical infection after intranasal inoculation of murine cytomegalovirus , 1978, Infection and immunity.